Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis
Related Experiment Video
Updated: Jul 13, 2025
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Anusha Shirwaikar Thomas1, Suresh T Chari2,3
1University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Purpose Of Review:
Immune checkpoint inhibitors (ICI) have revolutionized cancer care and work primarily by blocking CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), and/or PD-1 (programmed cell death protein 1), and/or PD-L1 (programmed death-ligand 1), thereby providing highly efficacious anti-tumor activity. However, this unmitigated immune response can also trigger immune related adverse events (irAEs) in multiple organs, with pancreatic irAEs (now referred to as type 3 Autoimmune pancreatitis (AIP) being infrequent.
Recent Findings:
Type 3 AIP is a drug-induced, immune mediated progressive inflammatory disease of the pancreas that may have variable clinical presentations viz., an asymptomatic pancreatic enzyme elevation, incidental imaging evidence of pancreatitis, painful pancreatitis, or any combination of these subtypes. Management is largely supportive with intravenous fluid hydration, pain control and holding the inciting medication. Steroids have not been shown to demonstrate a clear benefit in acute management. A rapid development pancreatic atrophy is observed on imaging as early as 1 year post initial injury. Type 3 AIP is a chronic inflammatory disease of the pancreas that though predominantly asymptomatic and mild in severity can lead to rapid organ volume loss regardless of type of clinical presentation and despite steroid therapy.
Insights
Immune checkpoint inhibitors can cause rare pancreatic side effects, known as type 3 autoimmune pancreatitis. This condition can lead to rapid pancreatic atrophy, even with supportive care.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Immune checkpoint inhibitors (ICI) like CTLA-4, PD-1, and PD-L1 blockade enhance anti-tumor immunity.
- ICI therapy can induce immune-related adverse events (irAEs) affecting various organs.
- Pancreatic irAEs, termed type 3 autoimmune pancreatitis (AIP), are infrequent complications of ICI therapy.
Purpose of the Study:
- To review the characteristics and management of type 3 autoimmune pancreatitis induced by immune checkpoint inhibitors.
- To highlight the potential for rapid pancreatic atrophy associated with this condition.
Main Methods:
- Literature review of studies on immune checkpoint inhibitors and autoimmune pancreatitis.
- Analysis of clinical presentations, diagnostic findings, and management strategies for type 3 AIP.
- Review of imaging evidence and progression of pancreatic changes.
Main Results:
- Type 3 AIP presents variably, including asymptomatic enzyme elevation, incidental findings, or painful pancreatitis.
- Management is primarily supportive, involving hydration, pain control, and drug withdrawal; steroids show limited acute benefit.
- Significant pancreatic atrophy can develop rapidly, observed as early as one year post-injury, irrespective of clinical presentation or steroid use.
Conclusions:
- Type 3 AIP is a chronic, immune-mediated pancreatic inflammation following ICI therapy.
- Despite often being asymptomatic or mild, it can lead to substantial and rapid pancreatic volume loss.
- Further research may be needed to optimize management and prevent long-term organ damage.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: